What is your presentation about?
Achieving glycemic targets early in the course of type 2 diabetes (T2D) may establish a legacy of lower A1C levels and lower risk of complications for patients with type 2 diabetes. Therapeutic Inertia (TI)—the failure of health care providers to initiate and intensify treatment when indicated, is a contributing factor to why achieving A1C targets has remained stagnant for 2 decades. A systematic review and meta-analysis supported by the ADA’s Overcoming Therapeutic Inertia Initiative investigated interventions that are effective in overcoming TI. Results of the meta-analysis will be reviewed, demonstrating that TI can be mitigated by empowering pharmacists, nurses and DCESs to independently initiate and intensify treatment supported by appropriate guidelines.
What makes this topic important in 2022?
Despite availability of effective treatment options, technology, and well-established guidelines, improvements in glycemic targets in the U.S. have lagged for over 20 years. Effective and efficient collaboration between all diabetes team members and primary care providers has the potential to achieve meaningful glycemic targets in patients with type 2 diabetes.
How did you become involved with this area of diabetes research or care?
I serve on the ADA Overcoming Therapeutic Inertia Steering Committee and am co-chair of the Patient and Professional Engagement Group. I have spent over four decades as a diabetes educator, clinic administrator, and ADA volunteer.
What are you most looking forward to at the 82nd Scientific Sessions?
Interacting with the best minds in diabetes management to once again learn, share, and be inspired by each other to carry on the mission of improving diabetes health outcomes.